Mostrar el registro sencillo del ítem

dc.contributor.authorRobledo, C.
dc.contributor.authorGarcía, J.L.
dc.contributor.authorGonzález, M.
dc.contributor.authorGutiérrez, N.C.
dc.contributor.authorHernández, J.A.
dc.contributor.authorSandoval, V.
dc.contributor.authorGarcía de Coca, A.
dc.contributor.authorRecio, I.
dc.contributor.authorRisueño, A.
dc.contributor.authorMartín-Núñez, G.
dc.contributor.authorGarcía, E.
dc.contributor.authorFisac, R.
dc.contributor.authorConde, J.
dc.contributor.authorde las Rivas, J.
dc.contributor.authorHernández, J.M.
dc.contributor.authorRodríguez-Vicente, Ana E. 
dc.date.accessioned2024-01-25T09:29:07Z
dc.date.available2024-01-25T09:29:07Z
dc.date.issued2012
dc.identifier.citationRodríguez Vicente, A.E., Robledo, C., García, J.L., González, M., Gutiérrez, N.C., Hernández, J.A., Sandoval, V., García de Coca, A., Recio, I., Risueño, A., Martín-Nuñez, G., García, E., Fisac, R., Conde, J., de las Rivas, J., Hernández, J.M. (2012).Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling. Annals of Oncology, 23 (8) pp 2138-2146. https://doi.org/10.1093/annonc/mdr579es_ES
dc.identifier.issn0923-7534
dc.identifier.urihttp://hdl.handle.net/10366/154677
dc.description.abstract[EN] Background: The presence of genetic changes is a hallmark of chronic lymphocytic leukemia (CLL). The most common cytogenetic abnormalities with independent prognostic significance in CLL are 13q14, ATM and TP53 deletions and trisomy 12. However, CLL displays a great genetic and biological heterogeneity. The aim of this study was to analyze the genomic imbalances in CLL cytogenetic subsets from both genomic and gene expression perspectives to identify new recurrent alterations. Patients and methods: The genomic imbalances and expression levels of 67 patients were analyzed. The novel recurrent abnormalities detected with bacterial artificial chromosome array were confirmed by FISH and oligonucleotide microarrays. In all cases, gene expression profiling was assessed. Results: Copy number alterations were identified in 75% of cases. Overall, the results confirmed FISH studies for the regions frequently involved in CLL and also defined a new recurrent gain on chromosome 20q13.12, in 19% (13/67) of the CLL patients. Oligonucleotide expression correlated with the regions of loss or gain of genomic material, suggesting that the changes in gene expression are related to alterations in copy number. Conclusion: Our study demonstrates the presence of a recurrent gain in 20q13.12 associated with overexpression of the genes located in this region, in CLL cytogenetic subgroups.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCLLes_ES
dc.subjectcytogenetic aberrationses_ES
dc.subjectgene expression profilees_ES
dc.subjectgenomic arrayses_ES
dc.subject.meshPain *
dc.subject.meshLeukemia *
dc.subject.meshGene Expression Profiling *
dc.titleIdentification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profilinges_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1093/annonc/mdr579es_ES
dc.subject.unesco3109.01 Anatomíaes_ES
dc.subject.unesco6310.03 Enfermedades_ES
dc.identifier.doi10.1093/annonc/mdr579
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccesses_ES
dc.journal.titleAnnals of Oncologyes_ES
dc.volume.number23es_ES
dc.issue.number8es_ES
dc.page.initial2138es_ES
dc.page.final2146es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsperfiles de expresión génica *
dc.subject.decsleucemia *
dc.subject.decsdolor *


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional